August - 2022

Aug 30, 2022

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases

Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom? Jia-Feng Wu, Published in Jul 2022, Gut Liver. Abstract During the past decade, we have entered an era of biologics for the treatment of Crohn’s disease and ulcerative colitis. The therapeutic goal of inflammatory bowel disease (IBD) management has evolved from symptom control and clinical remission to mucosal healing or even deep remission. Histological remission

IBDENC ENC

Aug 27, 2022

Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy

Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease. Ashkan Rezazadeh Ardabili, Steven Jeuring, Zlatan Mujagic, Liekele Oostenbrug, Mariëlle Romberg-Camps, Daisy Jonkers, Adriaan van Bodegraven, Marieke Pierik Published in Jul 2022, Alimentary pharmacology & therapeutics. Summary Background Thiopurines remain recommended as maintenance therapy in patients with inflammatory bowel dise

Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease

IBDENC ENC

Aug 24, 2022

Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease

Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study. Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim and Dae Ryong Kang Published in Jul 2022, Gut and LIVER. Abstract Background/Aims Inflammatory bowel disease (IBD) is associated with the occurrence of venous thromboembolism (VTE). However, to date, there have been few studies on the risk

IBDENC ENC

Aug 23, 2022

CD147 Targeting by AC-73 Induces Autophagy and Reduces Intestinal Fibrosis Associated

CD147 Targeting by AC-73 Induces Autophagy and Reduces Intestinal Fibrosis Associated with TNBS Chronic Colitis. Alessia Butera, Maria Teresa Quaranta, Luca Crippa, Isabella Spinello, Ernestina Saulle, Nazzareno Di Carlo, Doriana Campanile, Monica Boirivant, Catherine Labbaye Published in Jul 2022, Journal of Crohn's & colitis. Abstract Background and Aims Intestinal fibrosis is a common complication of inflammatory bowel diseases. Medical treatment of intestinal fibrosis is

IBDENC ENC

Aug 20, 2022

Real-world experience of switching from intravenous to subcutaneous vedolizumab treatment

Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona van Schaik, Jeroen Maljaars, Krisztina Gecse, Cyriel Ponsioen, Joep Grootjans, Jurij Hanzel, Greetje Tack, Jeroen Jansen, Frank Hoentjen, Nanne de Boer, Sander van der Marel, Gerard Dijkstra, Bas Oldenburg, Mark Löwenberg, Andrea van der Meulen, Geert D

IBDENC ENC

Aug 19, 2022

(Re)Appraising Remission in Ulcerative Colitis

Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT Published in Aug 2022, Inflammatory bowel diseases. Abstract As the therapeutic targets in ulcerative colitis (UC) shift from control of symptoms to mucosal healing and prevention of disease complications like disability, colectomy, and cancer, the definition of remission has evolved. The current definition of clinical remission is variable and is determined by the clinical context in which it is being used. This res

IBDENC ENC

Aug 18, 2022

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients

Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region. Peeyush Kumar, Sudheer K Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet

IBDENC ENC

Aug 13, 2022

Proposal of novel staging system CNM to predict postoperative recurrence of Crohn's disease

Proposal of novel staging system CNM (Crohn's primary site, nodes, mesentery) to predict postoperative recurrence of Crohn's disease. Guduru Venkat Rao, Partha Pal, Anuradha Sekaran, Pradeep Rebala, Manu Tandan, D Nageshwar Reddy Published in Aug 2022, Intestinal research. Abstract After oncologic resection, histological grading and staging of the tumor give important prognostic information about the future risk of recurrence and hence influence the subsequent management plan

IBDENC ENC

Aug 11, 2022

Risks of Melanoma and Nonmelanoma Skin Cancers Pre- and Post-Inflammatory Bowel Disease Diagnosis

Mariam Narous, Zoann Nugent, Harminder Singh, Charles N Bernstein Published in Aug 2022, Inflammatory bowel diseases. Abstract Background We compared risks of nonmelanoma skin cancers (NMSCs) and melanoma preceding and following a diagnosis of inflammatory bowel disease (IBD) and to evaluate the effect of thiopurines and anti-tumor necrosis factor α (anti-TNF-α) on skin cancer risk in IBD. Methods This was a retrospective, historical cohort study using the population-based Un

IBDENC ENC

Aug 11, 2022

Assessing the inflammatory severity of the terminal ileum in Crohn disease using radiomics

Assessing the inflammatory severity of the terminal ileum in Crohn disease using radiomics based on MRI. Honglei Ding, Jiaying Li, Kefang Jiang, Chen Gao, Liangji Lu, Huani Zhang, Haibo Chen, Xuning Gao, Kefeng Zhou & Zhichao Sun Published in Jul 2022, BMC medical imaging. Abstract Background Evaluating inflammatory severity using imaging is essential for Crohn’s disease, but it is limited by potential interobserver variation and subjectivity. We compared the efficiency of ma

IBDENC ENC

Aug 4, 2022

Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease

A Swaminathan, G M Borichevsky, T S Edwards, E Hirschfeld, T C Mules, C M Frampton, A S Day, M B Hampton, A J Kettle, R B Gearry Published in Jul 2022, Journal of Crohn's & colitis. Abstract Background and Aims Inflammatory bowel disease [IBD], consisting of Crohn’s disease [CD] and ulcerative colitis [UC], is a relapsing-remitting illness. Treat-to-target IBD management strategies require monitoring of gastrointestinal inflammation. This study aimed to investigate faecal mye

IBDENC ENC

Aug 2, 2022

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection

Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study. Henit Yanai, Anna Kagramanova, Oleg Knyazev, João Sabino, Shana Haenen, Gerassimos J Mantzaris, Katerina Mountaki, Alessandro Armuzzi, Daniela Pugliese, Federica Furfaro, Gionata Fiorino, David Drobne, Tina Kurent, Sharif Yassin, Nitsan Maharshak, Fabiana Castiglione, Roberto de Sire,

The Mission

Key Opinion Leaders

International

Advisory Board

Initiatives

Discuss a case

Journal Scan

Latest News

Education Hub

Gallery